POTS NET mRNA Functional Correlation With NET Activity

Status Enrolling by invitation

Clinical Trial Summary

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

Clinical Trial Description

Work from The Baker Institute in Melbourne, Australia has shown that there can be significant epigenetic modification of the Norepinephrine Transporter (NET). DNA Acetylation can be responsible for significant down-regulation of transcription. NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses.Very low levels of NET can produce a hyperadrenergic phenotype and can "cause" Postural Tachycardia Syndrome (POTS). The Baker Institute researchers have started using quantified NET mRNA levels from a peripheral blood sample to assess NET availability. This is a huge advance due to its simplicity, in contrast to a prior method which involved a vein biopsy to look at the level of protein expression. In this protocol, the investigators seek to assess whether these NET messenger RNA (mRNA) levels correlate with NET function. When NET transports NE back into presynaptic neurons, a high percentage gets converted to a metabolite (DHPG) and then released into the blood stream. Therefore, the ratio of DHPG:NE ratio is decreased with reduced NET activity. The investigators will assess this DHPG:NE ratio in POTS patients and control subjects from both plasma and urine samples. ;

Study Design

Related Conditions & MeSH terms

Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Syndrome
Tachycardia

Clinical Trial Details

NCT number	NCT03218761
Study type	Observational [Patient Registry]
Source	Vanderbilt University Medical Center
Contact
Status	Enrolling by invitation
Phase
Start date	July 14, 2017
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03124355` - Vagal Stimulation in POTS	Phase 1
Recruiting	`NCT04310644` - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed	`NCT03253120` - Alterations of Attention in POTS Depending on Body Position and Hydration	N/A
Completed	`NCT03919773` - IVIG (Gamunex-C) Treatment Study for POTS Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT01988883` - Modafinil and Cognitive Function in POTS	Early Phase 1
Active, not recruiting	`NCT01000350` - Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)	N/A
Recruiting	`NCT00409435` - A Study of Pyridostigmine in Postural Tachycardia Syndrome	Phase 2
Completed	`NCT00770484` - Effect of Exercise in OI	N/A
Completed	`NCT00581022` - Objective Sleep Disturbances in Orthostatic Intolerance
Terminated	`NCT00748228` - Dopamine in Orthostatic Tolerance	N/A
Active, not recruiting	`NCT05630040` - VNS for Long-COVID-19	N/A
Recruiting	`NCT04632134` - Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS)	N/A
Completed	`NCT00685919` - Peripheral Dopamine in Postural Tachycardia Syndrome	Phase 2/Phase 3
Completed	`NCT00061009` - Hypnosis in Autonomic Function	N/A
Recruiting	`NCT05618054` - Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?	N/A
Completed	`NCT01366963` - Cognitive Dysfunction in Postural Tachycardia Syndrome	N/A
Recruiting	`NCT05107635` - Inappropriate Sinus Tachycardia Registry
Terminated	`NCT02154009` - Clinical Autonomic Disorders: A Training Protocol
Completed	`NCT03602482` - Standing Cognition and Co-morbidities of POTS Evaluation	N/A
Completed	`NCT02167412` - EEG Characteristics in Youth POTS and/or Syncope

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.